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Abstract
Background: Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically
are centered on docetaxel-based chemotherapy. We previously reported that elevated miR-375 levels were
significantly associated with poor overall survival of mCRPC patients. In this study, we evaluated if miR-375 induced
chemo-resistance to docetaxel through regulating target genes associated with drug resistance.
Methods: We first compared miR-375 expression level between prostate cancer tissues and normal prostate tissues
using data from The Cancer Genome Atlas (TCGA). To examine the role of miR-375 in docetaxel resistance, we
transfected miR-375 using a pre-miRNA lentiviral vector and examined the effects of exogenously overexpressed
miR-375 on cell growth in two prostate cancer cell lines, DU145 and PC-3. To determine the effect of overexpressed
miR-375 on tumor growth and chemo-resistance in vivo, we injected prostate cancer cells overexpressing miR-375
into nude mice subcutaneously and evaluated tumor growth rate during docetaxel treatment. Lastly, we utilized
qRT-PCR and Western blot assay to examine two miR-375 target genes, SEC23A and YAP1, for their expression
changes after miR-375 transfection.
Results: By examining 495 tumor tissues and 52 normal tissues from TCGA data, we found that compared to
normal prostate, miR-375 was significantly overexpressed in prostate cancer tissues (8.45-fold increase, p value = 1.
98E-23). Docetaxel treatment induced higher expression of miR-375 with 5.83- and 3.02-fold increases in DU145 and
PC-3 cells, respectively. Interestingly, miR-375 appeared to play a dual role in prostate cancer proliferation. While
miR-375 overexpression caused cell growth inhibition and cell apoptosis, elevated miR-375 also significantly
reduced cell sensitivity to docetaxel treatment in vitro, as evidenced by decreased apoptotic cells. In vivo xenograft
mouse study showed that tumors with increased miR-375 expression were more tolerant to docetaxel treatment,
demonstrated by greater tumor weight and less apoptotic cells in miR-375 transfected group when compared to
empty vector control group. In addition, we examined expression levels of the two miR-375 target genes (SEC23A
and YAP1) and observed significant reduction in the expression at both protein and mRNA levels in miR-375
transfected prostate cancer cell lines. TCGA dataset analysis further confirmed the negative correlations between
miR-375 and the two target genes (r = −0.62 and −0.56 for SEC23A and YAP1, respectively; p < 0.0001).
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Conclusions: miR-375 is involved in development of chemo-resistance to docetaxel through regulating SEC23A and
YAP1 expression. Our results suggest that miR-375 or its target genes, SEC23A or YAP1, might serve as potential
predictive biomarkers to docetaxel-based chemotherapy and/or therapeutic targets to overcome chemo-resistance
in mCRPC stage.
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Background
Prostate cancer (PC) is the most common non-skin can-
cer and the second leading cause of cancer- related mor-
tality in men, with >220,000 newly diagnosed cases and
27,000 deaths annually in the United States [1]. Current
guidelines recommend that treatments should be con-
sidered based on tumor stage. Surgery and radiation
therapy are generally effective for early and localized
cancers [2]. Docetaxel is used as a standard first-line
standard chemotherapy and has shown a survival advan-
tage in metastatic castration-resistant PC (mCRPC), with
a median survival advantage of 2 to 3 months when
compared to mitoxantrone and improved quality of life
[3, 4]. However, a substantial proportion of men with
mCRPC do not benefit from docetaxel and those who
do benefit invariably progress and die from the disease.
Additionally, there has been a considerable expansion in
the therapeutic armamentarium with several novel op-
tions becoming available for treating mCRPC stage. This
has helped prolong life, but has also made clinical deci-
sion making complex in choosing between different op-
tions. In this study we attempted to characterize
molecular mechanisms for development of resistance to
docetaxel therapy in PC patients.
miRNAs are a conserved class of small noncoding
RNAs that have been recognized as key regulators of
gene expression at post-transcriptional level [5, 6]. They
are broadly involved in tumor proliferation, invasion,
angiogenesis, and drug resistance [5–8]. In recent stud-
ies, miRNAs including miR-148a [8], miR-200c [9], miR-
205 [2, 9], miR-21 [10], miR-31 [2], and miR-34 [11],
have been reported to regulate drug resistance in PC.
Characterization of miRNA involvement likely facilitate
predictive and prognostic markers of treatments as well
as molecular targets for drug development in this stage
and tumor type. miR-375 expression in tissue or circula-
tion has been shown to potentially serve as a biomarker
for PC diagnosis or prognosis [12–14]. We recently
showed significant association of elevated miR-375 levels
in plasma with poor overall survival of mCRPC patients
[13]. However, this finding is contradictory with other
report showing tumor suppressor activity of miR-375 in
multiple tumor types by targeting key oncogenes [15].
Although upregulated in primary PC, miR-375 is signifi-
cantly downregulated in multiple other tumors [15, 16].
To date, the biological role and mechanisms of action of
miR-375 in chemotherapy response of mCRPC are not
fully understood. A recent study in cervical cancer
showed that miR-375 is associated with paclitaxel treat-
ment response through regulation of epithelial–mesen-
chymal transition (EMT), leading to chemo-resistance
[17]. This study suggests that miR-375 may be involved
in the development of chemo-resistance in PC to com-
monly used anti-cancer drug, docetaxel.
In the present study, we performed a series of in vitro
and in vivo tests and found consistently higher expression
levels of miR-375 in PC tissues and docetaxel-treated PC
cells. Elevated miR-375 significantly reduced sensitivity of
PC cells to docetaxel treatment, as evidenced by reduced
apoptotic cells. Moreover, miR-375 overexpression in PC
xenograft tumors following lentivirus transfection contrib-
uted to development of resistance to docetaxel treatment.
Finally, our data demonstrated that miR-375 may confer
chemoresistance through reducing the levels of its target
genes SEC23A and YAP1.
Methods
Cell culture and chemicals
Human PC cell lines DU145 and PC-3 were purchased
from American Type Culture Collection (Manassas, VA,
USA), and cultured in RPMI 1640 media with 10 % fetal
bovine serum and penicillin and streptomycin (Gibco,
Carlsbad, CA, USA). The cell lines were maintained at
37 °C and 5 % CO2 in a humidified incubator. Docetaxel
was purchased from Cayman Chemical (MI, USA). The
cancer cell lines (DU145 and PC-3) were seeded 3 × 105
per well in six-well plates and incubated overnight, and
then treated with docetaxel for 72 h. After 72 h of
induction, cells were harvested for subsequent analyses.
Isolation of total RNA and qRT-PCR
Total RNA were extracted from harvested cells using the
Zymo Quick-RNA miniprep extraction kit (Zymo Re-
search, CA, USA) according to the manufacturer’s instruc-
tions. Quantitative reverse transcription PCR (qRT-PCR)
was conducted using the method as described previ-
ously18. For the detection of SEC23A and YAP1, 1 μg
of total RNA per sample was converted to cDNA using
the SuperScript VILO cDNA Synthesis Kit (Invitrogen,
Carlsbad, CA, USA). cDNAs were amplified and
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detected using SYBR Green PCR Kit (Qiagen, Valencia,
CA, USA). The GADPH was used as endogenous con-
trol for mRNA. For detection of the miRNA, the
cDNA products were synthesized using miScript Re-
verse Transcription Kit (Qiagen, Valencia, CA, USA).
The primers specific for miR-375 or endogenous
control RNU6B were purchased from Qiagen. qRT-
PCR was performed using miScript SYBR Green PCR
Kit (Qiagen). All reactions were run in triplicate on
Bio-Rad C1000 thermal cycler (CFX-96 real-time PCR
detection systems, Bio-Rad). The fold change of
miRNA or mRNA expression was calculated according
to the 2−ΔΔct method. The sequences of all primers are
given in Table 1.
Transfection with miR-375 mimics and negative controls
For transient transfection, miRNA mimics and inhibitors
were transfected into DU145 and PC-3 cells using Lipo-
fectamine RNAiMAX Reagent (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s protocol. The
miR-375 mimic and negative control were obtained from
Ambion (Life Technologies, Grand Island, NY, USA).
The final concentration of miR-375 mimic, and negative
control in the transfection system was 200 nM, respect-
ively. After 24 or 48 h, the cells were collected for subse-
quent flow cytometry, Western blotting and qRT-PCR.
Lentivirus transduction
To generate miR-375 stable transfectants, PC cell lines
(DU145 and PC-3) were transfected with lentiviral
expressing vectors, and stable clones were selected. The
lentivirus vector, hsa-mir-375 lentivirus or miR-negative
control lentivirus, was obtained from Biosettia (San
Diego, CA, USA) with a titer of 107 IU/mL. A total of
1 × 105 DU145 or PC-3 cells were plated in 6-well dishes
overnight, and 20 μL of the lentivirus diluted in 2 mL of
the Opti-MEM medium was treated in the presence of
5 μg/mL of polybrene (Sigma-Aldrich, St Louis,
Missouri, USA). After 24 h, the culture medium was
replaced by fresh medium and the transduced cells were
positively selected by continuous exposure to 2 μg/mL
puromycin (Invivogen, San Diego, CA, USA). At 14 days
after the selection, >90 % of the cells displayed red fluores-
cence at excitation/emission wavelengths of 587/610 nm.
qRT-PCR assays were used to detect the expression of
miR-375 in these stable cell lines.
Cell proliferation assay
Cell proliferation was evaluated using a Cell-Counting Kit
8 (CCK8), as described by the manufacturer (Dojindo
Molecular Technologies, Inc., Kumamoto, Japan). Two
thousands of DU145 or PC-3 cells per well were cultured
in 96-well plates and 10 μL of CCK-8 solution was added
to each well at the indicated time points after transfection.
Cells were further incubated for 2 h at 37 °C in a 5 % CO2
incubator. The absorbance was measured at 450 nm with
Multiscan FC Microplate Photometer (Thermo Fisher Sci-
entific, Rochester, NY, USA).
Flow cytometry
Cell apoptosis was detected using Annexin V-PE Apop-
tosis Detection Kit (BD Pharmingen, San Jose, CA, USA).
Cells in the logarithmic phase of growth were harvested
and washed twice in PBS. Based on the manufacturer’s
instruction, 1 × 106 cells were washed twice in PBS before
re-suspension in 1X Binding Buffer. 5 μl of PE Annexin V
and 5 μl 7-AAD were added and stained on ice for
30 min, followed by adding 400 μl of 1X Binding Buffer to
each tube. Stained cells were measured by flow cytometry
(FACSCalibur, BD Bioscience, Heidelberg, Germany)
using Cell Quest Pro software (BD Bioscience). The data
were analyzed using FlowJo9.1 software.
Western blot
Cells were lysed in RIPA buffer (1 % NP-40, 0.5 %
sodium deoxycholate, 0.1 % SDS in PBS). Complete pro-
tease inhibitor cocktail (Roche, Indianapolis, IN, USA)
was added to lysis buffer before use. Protein concentra-
tion was determined by Bio-Rad DC protein assay (Bio-
Rad, Hercules, CA, USA). 20ug of total protein from cell
lysate was subjected to SDS-PAGE and transferred to
nitrocellulose membrane. The membrane was blocked in
5 % non-fat milk in PBS overnight and incubated with
primary antibody. After washing for 30 min, secondary
goat anti-mouse IgG (Vector Co., Burlingame, CA,
USA) was applied to nitrocellulose membrane in TBS-
Tween for 1 h. After washing, the proteins of interest
were detected using Chemiluminescent HRP Antibody
Table 1 Primers for YAP1 and SEC23A quantification
Gene Primer sequences (5′–3′) Annealing Temperature (°C)
YAP1 Forward Primer 5′- TCC TTA ACA GTG GCA CCT ATC AC-3′ 58
Reverse Primer 5′- TCA CCT GTA TCC ATC TCA TCC A-3′
SEC23A Forward Primer 5′- TGC TAG GAA CTG GGC AGA TG-3′ 58
Reverse Primer 5′- AGC TGC CTC CTG GTC AAA AG-3′
GADPH Forward Primer 5′- CAC CAG GGC TGC TTT TAA CTC-3′ 58
Reverse Primer 5′- GAA GAT GGT GAT GGG ATT TC-3′
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Detection Kit (Denville Scientific, South Plainfield, NJ,
USA). Anti-SEC23A polyclonal antibody was purchased
from Sigma-Aldrich (St. Louis, MO, USA). Anti-β-
tubulin and anti-YAP antibodies were purchased from
Cell signaling technology (Danvers, MA, USA). The
protein signals were captured using an electrochemilu-
minescent system (PerkinElmer Life Science, Boston,
MA, USA).
Animal experiments
Female athymic nude mice at eight weeks of age were
purchased from the Jackson Laboratory (Bar Harbor,
ME). Animals were housed with wood chip bedding in
environmentally controlled, clean-air room with a 12-h
light–dark cycle and a relative humidity of 50 %. Drink-
ing water and diet were supplied ad libitum. The study
was approved by the Institutional Animal Care and Use
Committee at the Medical College of Wisconsin.
Mice were inoculated subcutaneously (s.c.) at two sites
per mouse with PC-3 cells stably transfected with lenti-
virus for either miR-375 or empty vector (n = 16). Xeno-
grafts were inoculated with 2.5 × 106 cells suspended in
200 μL PBS (phosphate-buffered saline) with 50 % Matri-
gel (BD Biosciences). When tumors reached an average
volume of 198 mm3, mice were randomly assigned into
vehicle control group (0.5 % DMSO in PBS) or 10 mg/
kg.bw docetaxel (Cayman Chemicals, Ann Arbor, MI).
Mice were administered intraperitoneally (i.p.) once per
week for 4 weeks. Mice were weighed and tumor volumes
were measured twice a week with digital caliper (volume
= π/6*length*width2). Experiments were stopped 7 days
after final injections. At the end point, mice were eutha-
nized by CO2 asphyxiation and tumor tissues were fixed
in zinc formalin solution overnight and stored in 70 %
ethanol for histopathology evaluation or flash frozen in
liquid nitrogen for RNA and protein evaluation.
Histology and Immunohistochemistry
Mouse xenografts were Zinc formalin fixed for 24–72 h
before paraffin processing on a Sakura VIP tissue proces-
sor. After paraffin embedding samples, 2 slides were
sectioned at 4um with 100um levels separating sections
for each xenograft and dried overnight at 45 °C. All
slides stained for Cleaved Caspase-3 (Biocare, CP-229)
were deparaffinized and subjected to antigen retrieval
with citrate buffer pH6 and EDTA pH9 respectively for
a total of 40 min. After peroxidase and protein blocking,
antibody was incubated at room temperature for 90 min.
The standard labelled streptavidin (HRP)-biotin detection
technique was used for visualization using 3,3′-diamino-
benzidine to detect the perioxidase. Positively stained cells
were counted in at least five fields from each area with
400× magnification. The results were expressed as the
average of positive cells per five 400× magnifications
(approximately corresponding to 0.035 mm2). Differences
of means per area between groups were determined by
ANOVA using SAS. Differences were considered signifi-
cant when P ˂ 0.05.
TCGA data analysis in PC patients
TCGA dataset was used to obtain both miRNA and mRNA
expressions, when available, from PC and normal tissue
samples. All miRNA/mRNA expression data were down-
loaded from TCGA data matrix (http://tcga- data.nci.nih.
gov/tcga/tcgaDownload.jsp). This dataset included 495 PC
tumor tissues and 54 partially matched normal tissues. To
prevent duplicates, when there was more than one dataset
for a particular sample, average values were used. The
expression values were pre-processed and normalized
according to ‘level 3’ specifications of TCGA (for details,
see http://cancergenome.nih.gov/).
miRNA target prediction and statistical analysis
The miRWalk database was used to identify potential tar-
gets of miRNA-375. 3′-UTRs with a seed match of at least
7 bases and a p-value <0.05 were searched using three data-
base algorithms: TargetScan, PITA and DIANA-mT. The
predicted miR-375 targets are listed in Additional file 1:
Table S1. Statistical data were presented as the mean ±
standard deviation (SD). Student’s t-test was performed for
comparisons using Excel. A value of p < 0.05 was consid-
ered statistically significant.
Results
miR-375 is upregulated in tumor tissues and is induced
by docetaxel in PC cell lines
We previously reported a significant association of ele-
vated plasma miR-375 expression with poor overall
survival in mCRPC stage. Since some of these patients
in this cohort had also received docetaxel chemotherapy
[13] we tested if miR-375 is involved in the development
of docetaxel resistance and may have impacted the over-
all survival. We first compared miR-375 expression
levels between PC tissues and normal prostate tissues in
TCGA dataset. We observed 8.45-fold increase of miR-
375 expression in PC tissues than in normal tissues
(Fig. 1a). To further study the impact of docetaxel
chemotherapy on the expression of miR-375 in PC cells,
we then treated DU145 and PC-3 cells with docetaxel in
different concentrations (1 nM, 2.5 nM, and 5 nM) for
72 h. qRT-PCR analysis showed that miR-375 expression
was significantly upregulated after docetaxel treatments
(Fig. 1b). Treatment of the cells with docetaxel at
concentrations of 1 and 2.5 nM, induced 5.83- and
14.01-fold increase in miR-375 expression in DU145
cells, respectively, and 3.02- and 2.53- fold increase in
PC-3 cells, respectively.
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To evaluate the long term effects of docetaxel on miR-
375 expression, DU145 and PC-3 cells were cultured
with 1 nM docetaxel. After 72 h of treatment, we re-
moved docetaxel from the culture media and continued
the cell culture until day 21. We performed qRT-PCR
and measured expression levels of miR-375 at days 0, 3,
7, 14, and 21, respectively. Our data showed docetaxel-
associated progressive upregulation of miR-375 expres-
sion in both DU145 and PC-3 cells. The miR-375
expression level reached a peak at day 7 in PC-3 cells, or
day 14 in DU145 cells, and gradually declined until day
21 (Fig. 1c). These findings suggest that the expression
level of miR-375 in PC is docetaxel-dependent. Because
miR-375 level keeps increase (in PC-3 cells) or remain
unchanged (in DU145) for several days after docetaxel
removal, this docetaxel-induced miR-375 upregulation
was more likely to be an indirect effect.
miR-375 contributes to docetaxel resistance in PC cell lines
To determine the effect of miR-375 on proliferation of PC
cell lines, PC-3 and DU145 cells were transiently trans-
fected with 200 nM miR-375 mimic. Cell proliferation was
assayed by the CCK-8 method. The proliferation rate of
PC-3 and DU145 cells at 72 h after transfection was sig-
nificantly reduced (P = 0.003 and P = 0.001, respectively)
when compared to that of miRNA negative control (see
Additional file 2: Figure S1). To evaluate the involvement
of miR-375 in regulation of docetaxel sensitivity, we stably
transfected a miR-375 expression lentivirus and control
vector into PC cell lines. As shown in Fig. 2a, qRT-PCR
analysis confirmed the high level expression of miR-375
after transfection. To determine the sensitivity of PC cells
to docetaxel, we performed a cell proliferation and cyto-
toxicity assay (CCK-8) at 48 h using different docetaxel
doses (0, 5, 10, 25, 50 and 100 nM). As shown in Fig. 2b,
miR-375 transfected cells consistently showed higher
survival rate (therefore, docetaxel resistance) in both PC-3
and DU145 cell lines. The IC50 values were increased in
PC-3 and DU145 with miR-375 overexpression (60.05 ±
1.63 and 21.55 ± 0.96 nM, respectively) when compared to
vector controls (19.98 ± 1.54 and 5.29 ± 0.57 nM, respect-
ively) (PC-3, P = 0.021; DU145, P = 0.033). To determine
whether the effects of miR-375 on cell proliferation were
related to apoptosis, we conducted an apoptosis assay by
flow cytometry. We first transfected PC cells with 200 nM
miR-375 mimic for 24 h and then treated the cells with
docetaxel (50 nM) for another 24 h. Our results showed
that ectopic miR-375 expression decreased docetaxel-
induced cellular apoptosis. For example, when comparing













Fig. 1 miR-375 expression in PC tissues and its response to docetaxel PC cell lines. a Overexpression of miR-375 in PC tissues. Normalized
miR-375 expression levels were downloaded from TCGA. Compared to normal prostate tissues, expression levels of miR-375 in PC tissues are
significantly higher. Number on the top of each box plot is mean value of miR-375 expression. b Response of miR-375 to docetaxel in PC cells.
miR-375 expression levels were measured by qRT-PCR under different concentrations of docetaxel. The result shows dose-dependent upregulation
of miR-375. Number on the top of each bar plot is mean fold change of miR-375 expression when compared to controls. c Dynamic expression
changes of miR-375 during and after docetaxel treatment. 1 nM docetaxel was used until 72 h. Expression level was measured at days 0, 3, 7, 14, and 21,
respectively. miR-375 expression was upregulated during treatment and gradually reduced after removal of docetaxel. MicroRNA expression values were
rescaled relative to the blank control
Wang et al. Molecular Cancer  (2016) 15:70 Page 5 of 11
positive cell fraction increased from 3.92 to 15.3 % in
control DU145 cells, while decreased from 13.2 to
6.34 % in miR-375 transfected DU145 cells. Similar data
were also observed in PC-3 cell line (Fig. 2c). Cells with
miR-375 overexpression is clearly resistant to docetaxel
treatment in PC cells.
miR-375 is involved in the development of docetaxel
resistance in PC cells grown as xenograft tumors in
nude mice
To further test for the involvement of miR-375 in doce-
taxel resistance, we injected the stably transfected cell
lines grown as xenograft tumors in athymic nude mice.
We observed consistently higher tumor volume in tu-
mors with miR-375 overexpression than tumors with
empty vector under docetaxel administration, in par-
ticular, at day 28 after initiation of docetaxel treatment
(Fig. 3a). At the end of experiment period, the mean
wet weight of tumors was significantly higher in miR-
375 transfected group than in empty vector control
group (p < 0.05) (Fig. 3b and c). Clearly, the higher
expression of miR-375 is also associated with docetaxel
resistance in vivo.
To further evaluate the potential effect of miR-375
expression on death in vivo, we tested the presence of
active caspase-3 by immunohistochemistry in xenograft
tumors. Caspase-3 is a cytosolic enzyme that is activated
only in cells committed to undergo apoptosis. The acti-
vation of caspase-3 precedes the development of the
classical morphological features of apoptosis. The immu-
nostaining analysis showed that miR-375 overexpression
tumors had significantly higher levels of activated
caspase-3 positive cells than empty vector control
tumors (11.13 ± 5.64 vs. 6.25 ± 2.84, P = 0.0043). How-
ever, miR-375 overexpression tumors treated with doce-
taxel showed lower levels of caspase-3 positive cells than
empty vector tumors treated with docetaxel (10.5 ± 5.16
vs. 18.67 ± 9.40, P = 0.0150) (Fig. 3d). This conflicting
result demonstrates that under the condition of doce-
taxel treatment the anti-apoptotic effect of miR-375
overexpression overshadows its growth inhibition. This
was in line with the in vitro experiments. Representative
immunostainings are shown in Additional file 3: Figure S2.
miR-375 regulates SEC23A and YAP1 expression
miR-375 has been shown to target YAP1 in lung cancer
cells [18] and also SEC23A at its 3′-UTR in PC cell lines
to regulate cell growth [16]. To investigate whether miR-
375 directly regulates YAP1 or SEC23A expression, we








Fig. 2 miR-375 induced docetaxel resistance in PC cells. a After miR-375 lentivirus transfection, both DU-145 and PC-3 cell lines show stably high
level expression. b PC cells were treated with different concentrations of docetaxel for 48 h. Cell proliferation assay shows that cells with miR-375
transfection are more tolerant to docetaxel toxic effect. c 24 h after miR-375 transfection, cells were treated with docetaxel (50 nM) for another
24 h. Flow cytometry analyses show that high levels of miR-375 protect cells from apoptosis in both PC-3 and DU145 cell lines. Fraction of
apoptotic cells are shown in lower right corners
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and evaluated the SEC23A and YAP1 mRNA expression
by qRT-PCR. Transfection with miR-375 in PC-3 cells
resulted in significant reduction of SEC23A and YAP1
mRNA expression with 31 and 78 % decreases, respect-
ively (Fig. 4a). Furthermore, Western blotting of PC-3
cells expressing miR-375 showed a significant reduction
in SEC23A and YAP1 protein levels (Fig. 4b). We also
evaluated if elevated miR-375 impacts the transcription
levels of its target genes in vivo in PC xenograft tumors.
Both qRT-PCR and Western blot analysis showed that
miR-375 transfection caused significant reduction of
SEC23A and YAP1 mRNA expression (Fig. 4c), and
protein (Fig. 4d) in xenograft tumors grown in mice.
miR-375 expression is inversely correlated with SEC23A
and YAP1 in PC tissues
To evaluate if miR-375 may target SEC23A and YAP1 in
patient-derived PC tissues, we first compared SEC23A and
YAP1 expression levels between PC tissues and normal
prostate tissues in TCGA data. The results showed that
SEC23A and YAP1 levels were significantly decreased in
PC tissues when compared to normal tissues (p < 0.0001)
(Fig. 5a and b). We then performed a correlation analysis
between the expression levels of miR-375 and its two
target genes. This analysis demonstrated that the levels of
SEC23A and YAP1 were inversely correlated with miR-
375 expression level (r = −0.62 for SEC23A and −0.56 for
YAP1, p < 0.05) (Fig. 5c and d). These data indicate that
the inhibitory effects of miR-375 on SEC23A and YAP1
are also relevant in clinical samples in PC patients.
Discussion
Docetaxel is a common chemotherapeutic agent used to
treat multiple malignancies including mCRPC stage.
However, there are no markers of response/resistance
known for docetaxel. Molecular profiling of miRNAs
may help in developing companion diagnostics in the
clinic to identify subgroups of patients destined to
respond to this commonly used chemotherapy and also
to understand the molecular mechanisms of chemo-
resistance [9, 10]. miRNA regulation of gene expression
has been shown to play an important role in the devel-
opment of cancer drug resistance. By directly targeting
protein-coding genes, miRNAs are able to inhibit genes
that are necessary for signaling pathways or drug-
induced apoptosis that render cells resistance20. Multiple
miRNAs have been found to be critical in the control of








Fig. 3 Effect of miR-375 on docetaxel resistance in xenograft mice. Nude mice were inoculated with PC-3 cells transfected miR-375 or control vector
to allow tumor development. Mice were intraperitoneally injected with 10 mg/kg docetaxel once a week. a Tumor volumes in the docetaxel-treated
mice are increased with time, in particular the xenograft tumors overexpressing miR-375. b Xenografts with empty control vector were significantly
smaller than the miR-375 overexpression group. Representative tumors from each group are shown. c Tumor weights at the end of the treatment
period (28 days after first docetaxel injection) were significantly higher in miR-375 group. Data are represented as the mean ± SD. (n = 6, P <0.05).
d Caspase-3 immunohistochemistry analyses of xenograft tumors with empty control vector or miR-375 lentivirus vector after docetaxel treatment.
Under docetaxel (DTX) treatment, less apoptotic cells were observed in miR-375 overexpressed xenograft tumors than miR-375 vector controls
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examined the influence of docetaxel on miR-375 expres-
sion and its target genes using in vitro and in vivo as-
says. Our results suggest that miR-375 contributes to the
development of chemo-resistance in PC.
Previous studies showed that miR-375 is down-
regulated in many types of cancer [15], and therefore,
miR-375 is believed to act as a critical tumor suppressor
by targeting important oncogenes, and modulating
cancer-related processes such as cell proliferation, apop-
tosis, invasion and migration, metastasis and autophagy
[15, 19–22]. However, miR-375 is also reported to be
upregulated in some cancer types including PC [15] and
higher expression of miR-375 is associated with PC stage
and lymph node metastasis [23]. We have previously
shown that elevated miR-375 is significantly associated
with poor overall survival in mCRPC patients [13].
Surprisingly, the current study demonstrated consistent
growth inhibition of elevated miR-375 in PC cell lines.
This unexpected growth inhibition seems contradictory
to poor overall survival in patients with higher level of
miR-375. However, further in vitro and in vivo study
showed that higher miR-375 also rendered resistance to
docetaxel treatment. This conflicting result suggests that
while high miR-375 causes cell growth arrest the
treatment with docetaxel may create an environment
that favors cell growth, possibly through inhibiting cell
apoptosis. The anti-apoptotic effect clearly overweighs
the cell growth inhibitory effect. Therefore, high level of
miR-375 is expected to promote tumor growth and
reduce overall survival during docetaxel treatment.
To further investigate a potential role of miR-375 in
docetaxel resistance, we performed qRT-PCR and
western blot analysis, and confirmed the association of
elevated miR-375 with decreased expression of two
target genes, SEC23A and YAP1. This inverse relation-
ship is also clearly evidenced in PC tissues of TCGA
dataset. It has been reported that YAP is a transcrip-
tional coactivator and functions as the major effector of
the Hippo tumor suppressor pathway, which controls
cell growth, tissue homeostasis, and organ size [24]. In-
hibition of YAP1 expression greatly reduces detachment-
induced apoptosis [25]. YAP1 and AR co-localize and
interact with each other predominantly within cell nuclei
by an androgen-dependent mechanism in a hormone
naive and an androgen-independent mechanism in
mCRPC cells [26]. The role of YAP1 in PC, however, is
not limited in AR sensitive cells. A new study [27] has
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Fig. 4 Expression of miR-375 and its target genes (YAP1 and SEC23A) in PC cells or xenograft tumors. a qRT-PCR analysis showed that YAP1 and
SEC23A expressions were downregulated after miR-375 transfection in PC-3 cells. * indicates statistically significant reduction. b Western blots
showed suppression of YAP1 and SEC23A proteins in the miR-375-transfected PC-3 cells. c qRT-PCR analysis showed that YAP1 and SEC23A
expression levels were lower in xenografts overexpressing miR-375. d Western blots showed suppression of YAP1 and SEC23A proteins in
xenograft tumors overexpressing miR-375. β-actin served as a loading control to normalize protein signal intensity
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Compared to low expression in LnCap cells, YAP1 is
highly expressed in more invasive cell lines including
PC3 and DU145. Ectopical expression of miR-375
significantly reduced the YAP1 expression of these cell
lines both in mRNA and protein level. This study
revealed that ZEB1-miR-375-YAP1 pathway regulates
epithelial plasticity in PC.
A cumulative evidence has shown that acquisition of
chemo-resistance in cancer cells is accompanied by
epithelial-mesenchymal transition (EMT) phenotype.
miR-375 is inversely correlated with EMT signature [27].
Knockdown of YAP1 phenocopied miR-375 overexpres-
sion. Another study shows that miR-375 mediated
chemo-resistance in cervical cancer by facilitating EMT
[17]. SEC23A, a member of the coatomer protein com-
plex II (COPII) machinery, is instrumental in altering
the tumor cell secretome in various cancers [28, 29].
The gene was reported to regulate the secretion of
metastasis-suppressive proteins [30] and is involved in
anti-tumorigenesis. Ectopic expression of SEC23A re-
duces growth properties while inhibition of SEC23A
enhances the growth properties of PC cell lines [16]. A
recent study shows that SEC23A is a novel target of
miR-375 and is significantly downregulated in PC cells
and tissues [31]. Potentially, overexpression of miR-375
in PC cells directly inhibits production of SEC23A, which
prevents the secretion of metastasis-suppressive proteins,
thus enabling the metastatic spread and colonization of
the cancer cells. Therefore, these experimental evidences
strongly support that miR-375 induces PC docetaxel
resistance by down-regulating SEC23A and YAP1.
Conclusion
We performed cell line and animal-based studies to
establish a role for miR-375 in docetaxel resistance.
The results from this study suggest that docetaxel may
further upregulate miR-375 expression during chemo-
therapy and confer chemo-resistance by inhibiting
expression of SEC23A and YAP1. This mechanistic
basis may explain (at least partially) the development
of docetaxel resistance. This study further confirms
that miR-375 is not only an important candidate bio-
marker for clinical outcome prediction but also a key
target for future therapeutic drug development with or
without targeting SEC23A and YAP1 activity. Further
understanding biological role of miR-375 in PC thera-
peutics will facilitate discovery of new treatment
















































Fig. 5 Inverse relationship of expression levels between miR-375 and its target genes (YAP1 and SEC23A) in TCGA dataset. a Compared to normal
prostate tissues, expression levels of SEC23A were significantly lower in PC tissues. b Compared to normal prostate tissues, expression levels of
YAP1 were significantly lower in PC tissues. c Negative correlation of miR-375 with SEC23A expression (Pearson’s correlation r = −0.62, P < 0.0001).
d Negative correlation of miR-375 with YAP1 expression (Pearson’s correlation r = −0.56 P < 0.0001)
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Additional files
Additional file 1: Table S1. miR-375 targeted genes.
(XLSX 400 kb)
Additional file 2: Figure S1. Higher miR-375 suppresses cell proliferation
in PC cells. Overexpression of miR-375 by transfection with 200 nM miR-375
mimic inhibited cell growth when compared to miRNA negative control in
PC-3 and DU145 cells at 72 h after transfection. (P < 0.01). (PPTX 82 kb)
Additional file 3: Figure S2. Representative immunohistochemistry
analysis of xenograft tumor tissues. Cells with active caspase-3 were
shown in brown color. A, B and C are representative images for a lower
fraction of apoptotic cells, a higher fraction of apoptotic cells, and
negative controls, respectively. (PPTX 1067 kb)
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